DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Samidorphan
Samidorphan
In Vitro Pharmacological Characterization of Buprenorphine
Federal Register/Vol. 86, No. 73/Monday, April 19, 2021/Rules
Removing Samidorphan from Schedule II
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior
Rxoutlook® 4Th Quarter 2020
21.8018.02000 FIRST ENGROSSMENT Sixty-Seventh Legislative Assembly ENGROSSED SENATE BILL NO
Drug Pipeline Monthly Update June 2021
W O 2019/165298 Al 29 August 2019 (29.08.2019) W IP0I PCT
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
A Meta-Analysis Comparing Short-Term Weight and Cardiometabolic
WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
Opioid Receptor Blocker Shows Promise in Phase II Depression Trial
Opioid System Modulation with Buprenorphine/Samidorphan Combination for Major Depressive Disorder: Two Randomized Controlled Studies
Opioid Receptor Research Using ALZET Osmotic Pumps
Rxoutlook® 3Rd Quarter 2020
Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
Top View
In Vitro Pharmacological Characterization of Buprenorphine
Endogenous Opioid System Dysregulation in Depression: Implications for New Therapeutic Approaches
PROGRAM BOOK Table of Contents
Federal Register/Vol. 85, No. 238/Thursday, December 10, 2020
A Review of Samidorphan: a Novel Opioid Antagonist
(Dsarm) Advisory Committee Meeting November 1, 2018
TAG Mail – 26 March 2020
Opioid System Is Necessary but Not Sufficient for Antidepressive Actions of Ketamine in Rodents
Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program
TAG Mail – 25 June 2020
List of Scheduling Actions, Controlled Substances And
Samidorphan: Discovery of a Critical Component of FDA-Approved LYBALVI
Samidorphan Attenuates Drug-Induced Increases in Extracellular Dopamine Concentrations and Drug Self-Administration in Rats Jacobi I
Osteoarthritis Guideline Appendix 4 – Search Strategies
Olanzapine and Samidorphan
Lybalvi™ (Olanzapine/Samidorphan) – New Drug Approval
I Compound- 1
Literature Search Strategy for Treatment of Stable
Enrolled Senate Bill No. 2059
Opioid Modulation with Buprenorphine/Samidorphan As
Buprenorphine/Samidorphan (BUP/SAM) NDA 210,417
Towards New Mechanisms: an Update on Therapeutics for Treatment-Resistant Major Depressive Disorder
Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through
Briefing Document
Olanzapine and Samidorphan) Tablets, for Oral Use Or Repeated Doses of Opioids May Lead to Fatal Opioid Intoxication, Initial U.S
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
2017 Medicines in Development for Mental Illnesses
In Vitro Pharmacological Characterization Of
Investigation of the Reinforcing Potential of Samidorphan and Naltrexone by Fixed
FORTY-THIRD ANNUAL REPORT of the ·RESEARCH ADVISORY PANEL of CALIFORNIA .2013
Antidepressant-Like Effects of Buprenorphine Are Mediated by Kappa Opioid Receptors
2016 Medicines in Development for Mental Health
Differential Effects of Opioid Receptor Modulators on Motivational and Stress-Coping Behaviors in the Back-Translational Rat IFN-Α Depression Model
The Influence of Ketamine on Drug Discovery in Depression
Use of Buprenorphine in Treatment Resistant Depression
Locomotor and Anti-Immobility Effects of Buprenorphine in Combination with the Opioid
US Department of Justice Drug Enforcement
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia